title: Resectability of primary gastroenteropancreatic neuroendocrine tumor as a prognostic factor for survival.
abstract: BACKGROUND
  Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) originate from gastrointestinal cells and pancreas; most are benign or well-differentiated. GEP-NET treatment objectives are tumor resection and reduction of tumor growth and dissemination, as well as symptom amelioration. We undertook this study to identify prognostic factors among patients with GEP-NETs.
  
  
  METHODS
  A total of 48 patients with histopathological diagnosis of GEP-NET were examined. Dependent variables were disease-free survival (DFS) and overall survival rates. Independent variables were age, gender, primary tumor size, resectability, metastatic disease, and histological degree.
  
  
  RESULTS
  In 48 patients (60.4% female, 39.6% male, median age 54 years), overall survival rate was 43.7%, and DFS was 33 months. The most common location was gastric. Factors related with the poorest prognosis were histological degree types 2 and 3, tumors >2 cm, metastatic disease, and primary tumor irresectability. For DFS, the only adverse factor was histological degree.
  
  
  CONCLUSIONS
  Patients with recurrence of GEP-NET had a poorer prognosis. Complete resection of the lesion with negative margins is the most determining prognostic factor for overrall survival in patients with GEP-NET.
authors.affiliation: Servicio de Sarcomas y Tubo Digestivo Alto, Hospital de Oncología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, DF, Mexico. rafael.medrano66@prodigy.net.mx
authors.forename: Rafael
authors.initials: R
authors.lastname: Medrano-Guzmán
authors.forename: Sergio César
authors.initials: SC
authors.lastname: López-García
authors.forename: Sergio
authors.initials: S
authors.lastname: Torres-Vargas
authors.forename: Domingo
authors.initials: D
authors.lastname: González-Rodríguez
authors.forename: Isabel
authors.initials: I
authors.lastname: Alvarado-Cabrero
mesh_terms: D000328:Adult; D000368:Aged; D002454:Cell Differentiation; D003430:Cross-Sectional Studies; D018572:Disease-Free Survival; D005260:Female; D005743:Gastrectomy / Q000706:statistics & numerical data; D005770:Gastrointestinal Neoplasms / Q000453:epidemiology / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008800:Mexico / Q000453:epidemiology; D008875:Middle Aged; D060787:Neoplasm Grading; D018358:Neuroendocrine Tumors / Q000453:epidemiology / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D010190:Pancreatic Neoplasms / Q000453:epidemiology / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D016577:Pancreaticoduodenectomy / Q000706:statistics & numerical data; D011379:Prognosis; D012008:Recurrence; D012189:Retrospective Studies